U54GM115516
Cooperative Agreement
Overview
Grant Description
Northern New England Clinical and Translational Research Network
Awardee
Funding Goals
THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS) SUPPORTS BASIC RESEARCH THAT INCREASES OUR UNDERSTANDING OF BIOLOGICAL PROCESSES AND LAYS THE FOUNDATION FOR ADVANCES IN DISEASE DIAGNOSIS, TREATMENT, AND PREVENTION. NIGMS ALSO SUPPORTS RESEARCH IN SPECIFIC CLINICAL AREAS THAT AFFECT MULTIPLE ORGAN SYSTEMS: ANESTHESIOLOGY AND PERI-OPERATIVE PAIN, CLINICAL PHARMACOLOGY ?COMMON TO MULTIPLE DRUGS AND TREATMENTS, AND INJURY, CRITICAL ILLNESS, SEPSIS, AND WOUND HEALING.? NIGMS-FUNDED SCIENTISTS INVESTIGATE HOW LIVING SYSTEMS WORK AT A RANGE OF LEVELSFROM MOLECULES AND CELLS TO TISSUES AND ORGANSIN RESEARCH ORGANISMS, HUMANS, AND POPULATIONS. ADDITIONALLY, TO ENSURE THE VITALITY AND CONTINUED PRODUCTIVITY OF THE RESEARCH ENTERPRISE, NIGMS PROVIDES LEADERSHIP IN SUPPORTING THE TRAINING OF THE NEXT GENERATION OF SCIENTISTS, ENHANCING THE DIVERSITY OF THE SCIENTIFIC WORKFORCE, AND DEVELOPING RESEARCH CAPACITY THROUGHOUT THE COUNTRY.
Grant Program (CFDA)
Place of Performance
Maine
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
COVID-19 $1,364,125 (3%) percent of this Cooperative Agreement was funded by COVID-19 emergency acts including the American Rescue Plan Act of 2021.
Amendment Since initial award the End Date has been extended from 06/30/22 to 09/30/24 and the total obligations have increased 892% from $3,998,350 to $39,649,479.
Amendment Since initial award the End Date has been extended from 06/30/22 to 09/30/24 and the total obligations have increased 892% from $3,998,350 to $39,649,479.
Mainehealth was awarded
Northern New England Clinical and Translational Research Network
Cooperative Agreement U54GM115516
worth $39,649,479
from the National Institute of Allergy and Infectious Diseases in July 2017 with work to be completed primarily in Maine United States.
The grant
has a duration of 7 years 2 months and
was awarded through assistance program 93.360 Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development.
The Cooperative Agreement was awarded through grant opportunity IDeA Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54 - Clinical Trial Optional).
Status
(Complete)
Last Modified 4/4/25
Period of Performance
7/3/17
Start Date
9/30/24
End Date
Funding Split
$39.6M
Federal Obligation
$0.0
Non-Federal Obligation
$39.6M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for U54GM115516
Transaction History
Modifications to U54GM115516
Additional Detail
Award ID FAIN
U54GM115516
SAI Number
U54GM115516-824130649
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NS00 NIH National Institute of General Medical Sciences
Funding Office
75NA00 NIH OFFICE OF THE DIRECTOR
Awardee UEI
MAYKB1LWD5U9
Awardee CAGE
1QZC8
Performance District
ME-90
Senators
Susan Collins
Angus King
Angus King
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute of General Medical Sciences, National Institutes of Health, Health and Human Services (075-0851) | Health research and training | Grants, subsidies, and contributions (41.0) | $40,478,868 | 96% |
| Public Health and Social Services Emergency Fund, Office of the Secretary, Health and Human Services (075-0140) | Health care services | Grants, subsidies, and contributions (41.0) | $1,364,125 | 3% |
Modified: 4/4/25